BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27693431)

  • 1. Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
    Patil H; Saxena SG; Barrow CJ; Kanwar JR; Kapat A; Kanwar RK
    Drug Discov Today; 2017 Jan; 22(1):111-119. PubMed ID: 27693431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent applications of chemosensitivity tests for colorectal cancer treatment.
    Yoon YS; Kim JC
    World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer.
    Corbo C; Cevenini A; Salvatore F
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
    Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
    Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
    [No Abstract]   [Full Text] [Related]  

  • 7. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.
    Akkad J; Bochum S; Martens UM
    Langenbecks Arch Surg; 2015 Feb; 400(2):129-43. PubMed ID: 25701352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
    Das V; Kalita J; Pal M
    Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 14. Transcriptome modeling and phenotypic assays for cancer precision medicine.
    Jeong E; Moon SU; Song M; Yoon S
    Arch Pharm Res; 2017 Aug; 40(8):906-914. PubMed ID: 28766239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.
    Gatalica Z; Vranic S; Xiu J; Swensen J; Reddy S
    Fam Cancer; 2016 Jul; 15(3):405-12. PubMed ID: 26875156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients.
    Strambu V; Garofil D; Pop F; Radu P; Bratucu M; Popa F
    J Med Life; 2014 Mar; 7(1):17-26. PubMed ID: 24653752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating biomarkers in colorectal cancer trials in the West and China.
    Tejpar S; Shen L; Wang X; Schilsky RL
    Nat Rev Clin Oncol; 2015 Sep; 12(9):553-60. PubMed ID: 25963094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.
    Palma S; Zwenger AO; Croce MV; Abba MC; Lacunza E
    Clin Colorectal Cancer; 2016 Jun; 15(2):104-15. PubMed ID: 26777471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
    De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M
    World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
    Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
    Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.